L Chapuis, B Ji, C Truffot-Pernot, RJ O'Brien, MC Raviglione and JH Grosset
Faculte de Medecine, Pitie-Salpetriere, Paris, France.

The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice. After infection with a small inoculum of Mycobacterium tuberculosis H37Rv, normal mice developed a chronic and nonfatal infection, and the bacterial population became relatively stable after an initial period of limited multiplication. On the other hand, nude mice developed an acute and fatal infection, and all untreated mice died within 5 wk, with very high colony-forming-unit (CFU) counts in their organs. Various degrees of bactericidal activity were shown in normal mice after daily treatment with rifampin (RMP) plus pyrazinamide (PZA) for 13 wk, INH daily for 26 wk, or RPT once weekly for 13 or 26 wk or once fortnightly for 26 wk. The activity of RPT was significantly enhanced when INH was added at the same dosing frequency. In nude mice the response of M. tuberculosis infection to certain regimens was less favorable than that in normal mice, suggesting that preventive therapy may be less effective in severely immunodeficient hosts even during treatment. After chemotherapy was stopped, virtually all nude mice relapsed within 12 wk regardless of the regimen administered, whereas no or very few relapses were observed in normal mice that had been treated with RMP+PZA daily for 13 wk, or RPT alone or RPT+INH once weekly for 26 wk. The latter three regimens and RPT+INH once weekly for 13 wk may be applied for fixed-duration preventive therapy in human immunodeficiency virus (HIV)-negative subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. Schechter, R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 922 - 926. [Abstract] [Full Text] [PDF]

				N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3482 - 3486. [Abstract] [Full Text] [PDF]

				A. M. Lenaerts, S. E. Chase, and M. H. Cynamon Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3167 - 3168. [Abstract] [Full Text]

				N. DANIEL, N. LOUNIS, B. JI, R. J. O'BRIEN, A. VERNON, L. J. GEITER, M. SZPYTMA, C. TRUFFOT-PERNOT, G. HEJBLUM, and J. GROSSET Antituberculosis Activity of Once-weekly Rifapentine-containing Regimens in Mice . Long-term Effectiveness with 6- and 8-Month Treatment Regimens Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1572 - 1577. [Abstract] [Full Text]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				A. M. J. A. Lenaerts, S. E. Chase, A. J. Chmielewski, and M. H. Cynamon Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2356 - 2360. [Abstract] [Full Text]

				E. Miyazaki, R. E. Chaisson, and W. R. Bishai Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2126 - 2130. [Abstract] [Full Text]

				J. V. Brooks and I. M. Orme Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model Antimicrob. Agents Chemother., November 1, 1998; 42(11): 3047 - 3048. [Abstract] [Full Text]

				R. J. O'Brien and A. A. Vernon New Tuberculosis Drug Development . How Can We Do Better? Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1705 - 1707. [Full Text] [PDF]

				J. GROSSET, N. LOUNIS, C. TRUFFOT-PERNOT, R. J. O'BRIEN, M. C. RAVIGLIONE, and B. JI Once-weekly Rifapentine-containing Regimens for Treatment of Tuberculosis in Mice Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1436 - 1440. [Abstract] [Full Text]